US-based CDMO Catalent is joining forces with compatriot drug discovery company Exelixis to develop multiple antibody-drug conjugates (ADCs). The company’s Redwood...
07.03.2016
- French pharmaceutical company Ipsen is paying up to $855 million for the rights to Exelixis’ cancer drug Cabozantinib. Under the deal, Exelixis gains exclusive commercialization...
